Efficacy and safety of aspirin combined with cilostazol after stenting: a retrospective study from 2019 to 2021

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063994

Enrollment

Unknown

Registered

2022-09-22

Start date

2022-09-23

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Cilostazol group:Cliostazol combined with aspirin

Clopidogrel group:Clopidogrel combine with aspirin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years; 2. The patient had a history of cerebral infarction and had undergone head and neck artery stenting during hospitalization; 3. Aspirin combined with cilostazol (aspirin 100mg, QD; Cilostazol 100mg, bid), or aspirin plus clopidogrel (aspirin 100mg, qd; Clopidogrel 75mg, qd) dual antibody therapy; 4. The duration of study drug treatment from the perioperative period was >=3 months.

Exclusion criteria

Exclusion criteria: 1. Concurrent use of other anticoagulant, antiplatelet, defibrination or other agents that affect coagulation function during the study drug administration; 2. The survival time of patients after head and neck stent implantation was less than 1 year due to various reasons; 3. Patients with severe heart, liver and kidney insufficiency; 4. There is coagulopathy, active bleeding or bleeding tendency.

Design outcomes

Primary

Measure	Time frame
Modified Rankin score;Clinical outcomes;Bleeding events;Adverse reactions;	—

Countries

China

Contacts

Public ContactShao Tengfei

Affiliated Drum Tower Hospital of Nanjing University Medical School

shaotf@123.com+86 18913898337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026